The TIMI Study Group has received significant research grant support from Accumetrics, Amgen, AstraZeneca, Bayer Healthcare, Beckman-Coulter, Biosite, Bristol-Myers Squibb, CV Therapeutics, Daiichi Sankyo, Eisai Medical Research, Eli Lilly and Co., Genentech, GlaxoSmithKline, Integrated Therapeutics, Johnson & Johnson, Merck and Company, Millennium Pharmaceuticals, Nanosphere, Novartis Pharmaceuticals, Nuvelo, Ortho-Clinical Diagnostics, Pfizer, Roche Diagnostics, Sanofi-Aventis, Sanofi-Synthelabo, Schering-Plough, Siemens, and Singulex. Dr. Morrow has received honoraria for educational presentations from CV Therapeutics, Eli Lilly, and Sanofi-Aventis; served as a consultant for Beckman Coulter, Critical Diagnostics, CV Therapeutics, Sanofi-Aventis, Schering Plough, and Siemens; and is a paid member of a Clinical Events Committed for AstraZeneca. Dr. Scirica is a consultant for, educational presenter for, and has received research support from CVT/Gilead, and has received research support from Roche Diagnostics. Dr. Sabatine has received research support from CV Therapeutics and OrthoClinical Diagnostics. Dr. de Lemos has received grant support and consulting income from Biosite and Roche Diagnostics. Dr. Jarolim has received research support from Amgen, Beckman-Coulter, OrthoClinical Diagnostics, Roche Diagnostics, and Siemens Healthcare Diagnostics; and honoraria for educational presentations from OrthoClinical Diagnostics. Dr. Braunwald is the Chairman of the TIMI Study Group at the Brigham and Women's Hospital. Dr. Braunwald has received honorarium from Bayer AG, CV Therapeutics, Daiichi Sankyo, Eli Lilly, Merck & Co., Momenta, Schering-Plough, Sanofi-Aventis, Cytokinetics, Genzyme, GlaxoSmithKline, and Broadview Ventures.